<p>根據 Orca Wealth Management LLC 最近向證券交易委員會（SEC）提交的 13F 表格，該公司在第四季度購買了雅培（NYSE:ABT - 免費報告）的新頭寸。該公司購買了 2,548 股該醫療產品製造商的股票，價值約為 288,000 美元。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>雅培將在 2025 年超越醫療股票</li>
</ul>
<p>其他機構投資者和對沖基金最近也買賣了該公司的股票。Bath Savings Trust Co 在第四季度將其在雅培的股份提高了 3.7%。Bath Savings Trust Co 現在擁有 166,132 股雅培的股票，價值為 18,791,000 美元，此前在上個季度又購買了 5,881 股。Simplify Asset Management Inc.在第三季度將其在雅培的股份提高了 67.3%。Simplify Asset Management Inc.現在擁有 14,083 股雅培的股票，價值為 1,606,000 美元，此前在此期間又購買了 5,664 股。Pensionfund Sabic 在第四季度購買了雅培的新頭寸，價值約為 2,828,000 美元。Sequoia Financial Advisors LLC 在第三季度將其在雅培的股份增加了 19.6%。Sequoia Financial Advisors LLC 現在擁有 193,764 股雅培的股票，價值為 22,091,000 美元，此前在此期間又購買了 31,720 股。最後，Tidal Investments LLC 在第三季度將其在雅培的持股提高了 30.5%。Tidal Investments LLC 現在擁有 107,308 股雅培的股票，價值為 12,234,000 美元，此前在上個季度又購買了 25,052 股。目前，75.18% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>華爾街分析師觀點</h2>
<p>一些股票分析師最近對 ABT 股票發佈了報告。摩根士丹利在 2023 年 10 月 17 日的研究報告中將雅培的目標價從 107.00 美元提高到 117.00 美元，並給予該股票 “持平” 評級。瑞穗在 2023 年 10 月 17 日的報告中將雅培的目標價從 115.00 美元提高到 130.00 美元，並給予該股票 “中性” 評級。巴克萊在週一的研究報告中重申了 “增持” 評級，並將雅培的目標價從 149.00 美元上調至 158.00 美元。傑富瑞金融集團在 2023 年 10 月 17 日的研究報告中將雅培的目標價從 120.00 美元提高到 125.00 美元，並給予該股票 “持有” 評級。最後，雷蒙德·詹姆斯在 2023 年 10 月 14 日的研究報告中重申了 “買入” 評級，並將雅培的目標價從 122.00 美元上調至 129.00 美元。四位投資分析師對該股票給予了持有評級，十三位分析師給予了買入評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，平均目標價為 133.06 美元。</p>
<ul>
<li>這些是值得持有的頂級健康股票</li>
</ul>
<p><strong>查看我們對雅培的最新分析</strong></p>
<h2>雅培股票表現</h2>
<p>雅培（NYSE ABT）週三開盤價為 127.28 美元。該股票的 50 日移動平均線為 115.50 美元，200 日移動平均線為 113.64 美元。雅培的 12 個月低點為 99.71 美元，12 個月高點為 129.85 美元。該股票的市值為 2207.6 億美元，市盈率為 16.64，PEG 比率為 2.51，貝塔值為 0.73。該公司的流動比率為 1.60，速動比率為 1.14，債務股本比率為 0.32。</p>
<ul>
<li>MarketBeat 週迴顧 – 10/14 - 10/18</li>
</ul>
<p>雅培（NYSE:ABT - 獲取免費報告）在 2023 年 1 月 22 日發佈了季度財報。該醫療產品製造商報告每股收益（EPS）為 1.34 美元，符合市場共識預期的 1.34 美元。該公司在本季度的收入為 109.7 億美元，而分析師預期為 110.3 億美元。雅培的淨利潤率為 31.95%，股本回報率為 20.74%。與去年同期相比，雅培的收入增長了 7.2%。去年同期，該公司每股收益為 1.19 美元。賣方分析師預計雅培在當前財政年度的每股收益將達到 5.15 美元。</p>
<h2>雅培增加股息</h2>
<p>該公司最近還披露了季度股息，將於 2024 年 2 月 14 日支付。2024 年 1 月 15 日的股東將獲得每股 0.59 美元的股息。該股息的除息日期為 2024 年 1 月 15 日。這比雅培之前的季度股息 0.55 美元有所增加。這相當於每年 2.36 美元的股息，股息收益率為 1.85%。雅培的派息比率目前為 30.85%。</p>
<h2>雅培公司簡介</h2>
<p>（免費報告）</p>
<p>雅培及其子公司在全球範圍內發現、開發、製造和銷售醫療產品。它分為四個部門：成熟藥品、診斷產品、營養產品和醫療器械。該公司提供用於治療胰腺外分泌功能不全、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症狀、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，勝過雅培</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>調查顯示：2025 年遠程工作者和商業交易的 150 家最佳咖啡店</li>
<li>如何最有效地使用 MarketBeat 財報篩選器</li>
<li>艾利 Lilly 的未來會怎樣？</li>
<li>安靜期到期的解釋</li>
<li>甲骨文股票下跌近 14%——現在是買入的時機嗎？</li>
</ul>
<p><strong>想看看其他對雅培持有股份的對沖基金嗎？</strong> 訪問 HoldingsChannel.com，獲取雅培（NYSE:ABT - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在雅培嗎？</h2>
<p>在考慮雅培之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而雅培並不在名單上。</p>
<p>雖然雅培目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

雅培

<p>Orca Wealth Management LLC 在第四季度收購了雅培（NYSE:ABT）的新頭寸，購買了 2,548 股，價值約為 288,000 美元。其他機構投資者也增加了對雅培的持股。分析師們提高了該股票的目標價，平均目標為 133.06 美元，市場共識評級為 “適度買入”。雅培的股票開盤價為 127.28 美元，市值為 2207.6 億美元。該公司最近報告每股收益為 1.34 美元，並宣佈將股息提高至每股 0.59 美元，股息將在 2 月 14 日支付</p>

<p>Orca Wealth Management LLC bought a new position in Abbott Laboratories (NYSE:ABT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,548 shares of the healthcare product maker's stock, valued at approximately $288,000.</p>
<div class="lb-trans"><p>根據 Orca Wealth Management LLC 最近向證券交易委員會（SEC）提交的 13F 表格，該公司在第四季度購買了雅培（NYSE:ABT - 免費報告）的新頭寸。該公司購買了 2,548 股該醫療產品製造商的股票，價值約為 288,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>Abbott Laboratories Will Outperform Healthcare Stocks in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培將在 2025 年超越醫療股票</li>
</ul>
</div><p>Other institutional investors and hedge funds also recently bought and sold shares of the company. Bath Savings Trust Co lifted its stake in shares of Abbott Laboratories by 3.7% during the 4th quarter. Bath Savings Trust Co now owns 166,132 shares of the healthcare product maker's stock valued at $18,791,000 after buying an additional 5,881 shares in the last quarter. Simplify Asset Management Inc. boosted its stake in shares of Abbott Laboratories by 67.3% during the 3rd quarter. Simplify Asset Management Inc. now owns 14,083 shares of the healthcare product maker's stock worth $1,606,000 after purchasing an additional 5,664 shares during the period. Pensionfund Sabic bought a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $2,828,000. Sequoia Financial Advisors LLC increased its stake in Abbott Laboratories by 19.6% in the third quarter. Sequoia Financial Advisors LLC now owns 193,764 shares of the healthcare product maker's stock worth $22,091,000 after purchasing an additional 31,720 shares during the period. Finally, Tidal Investments LLC lifted its holdings in Abbott Laboratories by 30.5% during the 3rd quarter. Tidal Investments LLC now owns 107,308 shares of the healthcare product maker's stock valued at $12,234,000 after buying an additional 25,052 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金最近也買賣了該公司的股票。Bath Savings Trust Co 在第四季度將其在雅培的股份提高了 3.7%。Bath Savings Trust Co 現在擁有 166,132 股雅培的股票，價值為 18,791,000 美元，此前在上個季度又購買了 5,881 股。Simplify Asset Management Inc.在第三季度將其在雅培的股份提高了 67.3%。Simplify Asset Management Inc.現在擁有 14,083 股雅培的股票，價值為 1,606,000 美元，此前在此期間又購買了 5,664 股。Pensionfund Sabic 在第四季度購買了雅培的新頭寸，價值約為 2,828,000 美元。Sequoia Financial Advisors LLC 在第三季度將其在雅培的股份增加了 19.6%。Sequoia Financial Advisors LLC 現在擁有 193,764 股雅培的股票，價值為 22,091,000 美元，此前在此期間又購買了 31,720 股。最後，Tidal Investments LLC 在第三季度將其在雅培的持股提高了 30.5%。Tidal Investments LLC 現在擁有 107,308 股雅培的股票，價值為 12,234,000 美元，此前在上個季度又購買了 25,052 股。目前，75.18% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of equities analysts have recently issued reports on ABT shares. Morgan Stanley increased their price target on Abbott Laboratories from $107.00 to $117.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Thursday, October 17th. Mizuho raised their price target on Abbott Laboratories from $115.00 to $130.00 and gave the stock a &#34;neutral&#34; rating in a report on Thursday, October 17th. Barclays reiterated an &#34;overweight&#34; rating and issued a $158.00 target price (up from $149.00) on shares of Abbott Laboratories in a research note on Monday. Jefferies Financial Group lifted their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a &#34;hold&#34; rating in a research note on Thursday, October 17th. Finally, Raymond James reiterated a &#34;buy&#34; rating and set a $129.00 price objective (up from $122.00) on shares of Abbott Laboratories in a research note on Monday, October 14th. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average price target of $133.06.</p>
<div class="lb-trans"><p>一些股票分析師最近對 ABT 股票發佈了報告。摩根士丹利在 2023 年 10 月 17 日的研究報告中將雅培的目標價從 107.00 美元提高到 117.00 美元，並給予該股票 “持平” 評級。瑞穗在 2023 年 10 月 17 日的報告中將雅培的目標價從 115.00 美元提高到 130.00 美元，並給予該股票 “中性” 評級。巴克萊在週一的研究報告中重申了 “增持” 評級，並將雅培的目標價從 149.00 美元上調至 158.00 美元。傑富瑞金融集團在 2023 年 10 月 17 日的研究報告中將雅培的目標價從 120.00 美元提高到 125.00 美元，並給予該股票 “持有” 評級。最後，雷蒙德·詹姆斯在 2023 年 10 月 14 日的研究報告中重申了 “買入” 評級，並將雅培的目標價從 122.00 美元上調至 129.00 美元。四位投資分析師對該股票給予了持有評級，十三位分析師給予了買入評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，平均目標價為 133.06 美元。</p>
</div><ul>
<li>These Are The Top Health Stocks to Own for Buy-and-Hold Investing</li>
</ul>
<div class="lb-trans"><ul>
<li>這些是值得持有的頂級健康股票</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on Abbott Laboratories</strong></p>
<div class="lb-trans"><p><strong>查看我們對雅培的最新分析</strong></p>
</div><h2>Abbott Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>雅培股票表現</h2>
</div><p>NYSE ABT opened at $127.28 on Wednesday. The stock has a 50-day moving average of $115.50 and a 200 day moving average of $113.64. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $129.85. The stock has a market capitalization of $220.76 billion, a price-to-earnings ratio of 16.64, a PEG ratio of 2.51 and a beta of 0.73. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.</p>
<div class="lb-trans"><p>雅培（NYSE ABT）週三開盤價為 127.28 美元。該股票的 50 日移動平均線為 115.50 美元，200 日移動平均線為 113.64 美元。雅培的 12 個月低點為 99.71 美元，12 個月高點為 129.85 美元。該股票的市值為 2207.6 億美元，市盈率為 16.64，PEG 比率為 2.51，貝塔值為 0.73。該公司的流動比率為 1.60，速動比率為 1.14，債務股本比率為 0.32。</p>
</div><ul>
<li>MarketBeat Week in Review – 10/14 - 10/18</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 10/14 - 10/18</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.34. The firm had revenue of $10.97 billion during the quarter, compared to analysts' expectations of $11.03 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. Abbott Laboratories's revenue was up 7.2% compared to the same quarter last year. During the same period last year, the business earned $1.19 earnings per share. Sell-side analysts anticipate that Abbott Laboratories will post 5.15 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）在 2023 年 1 月 22 日發佈了季度財報。該醫療產品製造商報告每股收益（EPS）為 1.34 美元，符合市場共識預期的 1.34 美元。該公司在本季度的收入為 109.7 億美元，而分析師預期為 110.3 億美元。雅培的淨利潤率為 31.95%，股本回報率為 20.74%。與去年同期相比，雅培的收入增長了 7.2%。去年同期，該公司每股收益為 1.19 美元。賣方分析師預計雅培在當前財政年度的每股收益將達到 5.15 美元。</p>
</div><h2>Abbott Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>雅培增加股息</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be given a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, January 15th. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.55. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.85%. Abbott Laboratories's payout ratio is currently 30.85%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度股息，將於 2024 年 2 月 14 日支付。2024 年 1 月 15 日的股東將獲得每股 0.59 美元的股息。該股息的除息日期為 2024 年 1 月 15 日。這比雅培之前的季度股息 0.55 美元有所增加。這相當於每年 2.36 美元的股息，股息收益率為 1.85%。雅培的派息比率目前為 30.85%。</p>
</div><h2>Abbott Laboratories Profile</h2>
<div class="lb-trans"><h2>雅培公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培及其子公司在全球範圍內發現、開發、製造和銷售醫療產品。它分為四個部門：成熟藥品、診斷產品、營養產品和醫療器械。該公司提供用於治療胰腺外分泌功能不全、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症狀、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]</li>
<li>How to Most Effectively Use the MarketBeat Earnings Screener</li>
<li>What Does the Future Hold for Eli Lilly?</li>
<li>Quiet Period Expirations Explained</li>
<li>Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過雅培</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>調查顯示：2025 年遠程工作者和商業交易的 150 家最佳咖啡店</li>
<li>如何最有效地使用 MarketBeat 財報篩選器</li>
<li>艾利 Lilly 的未來會怎樣？</li>
<li>安靜期到期的解釋</li>
<li>甲骨文股票下跌近 14%——現在是買入的時機嗎？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對雅培持有股份的對沖基金嗎？</strong> 訪問 HoldingsChannel.com，獲取雅培（NYSE:ABT - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在雅培嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮雅培之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而雅培並不在名單上。</p>
</div><p>While Abbott Laboratories currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Orca Wealth Management LLC 在雅培公司（NYSE:ABT）中獲得了新的頭寸